Physician profile
Diane B Ebaugh
NPI 1215997796
$10,883.33
in general payments reported to CMS, 2019-2025
56 companies · $1,609 in 2025
The $1,609 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,737 · 2020: $1,030 · 2021: $1,679 · 2022: $1,624 · 2023: $1,696 · 2024: $1,508 · 2025: $1,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,700 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,699.57 |
| Education | $112.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,667.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,610.50 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $735.77 | 2019-2025 | |
| Abbvie INC. | $686.07 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astellas Pharma US INC | $641.60 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $625.03 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $549.15 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $493.26 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $422.92 | 2019-2025 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $306.68 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $289.66 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Bayer Healthcare Pharmaceuticals INC. | $191.31 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $184.15 | 2019-2025 | Trintellix, Glassia |
| Sanofi-Aventis U.S. LLC | $183.15 | 2019-2021 | |
| Amarin Pharma, INC. | $175.32 | 2019-2021 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Ebaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.